Avsnitt
-
Tune in to this must-listen episode with Dr. Anna Kirby, Consultant Clinical Oncologist at the Royal Marsden Hospital and Institute of Cancer Research, London, UK.
She shares insights into the challenges and successes of designing and conducting breast cancer radiotherapy trials, including FAST-FORWARD Boost, and highlights the crucial role of patient and public involvement.
As a past president of ESTRO, Dr. Kirby also reflects on the impact of international guidelines, discussing both their successful implementation and the challenges faced in ensuring widespread adoption.
-
Join us for an engaging episode with Professor Declan Murphy, Co-host of the GU Cast Podcast, Director of GU Oncology and Robotic Surgery at the Peter MacCallum Cancer Centre, Melbourne, Australia. We explore the challenges of surgeon heterogeneity, the critical role of equipoise, and why involving urologists early is essential for the success of clinical trials. Discover how multidisciplinary collaboration, cutting-edge innovation, and advanced imaging are transforming the landscape of urological surgical trials!
-
Saknas det avsnitt?
-
Join us for this must-listen episode with Dr. Renu Eapen, co-host of GU Cast podcast! She shares insights on balancing clinical practice and research and navigating PhD challenges. We discuss the importance of good mentorship and women’s representation in the field. We also hear about her exciting work on the Lutectomy trial.
-
In this episode, Mr Ashwin Sachdeva, Consultant Urologist and Academic Clinical Lecturer at the University of Manchester discusses the following:
00:00 Introduction
02:10 Utilising NHS Data for long-term follow-up
04:40 Fracture rates and hormone therapy in prostate cancer
07:05 Challenges in trial follow-up and data collection
11:18 Imaging and its role in prostate cancer
17:58 Prospective imaging collection in the STAMPEDE trial
22:32 Balancing surgery and research
26:31 Future directions in prostate cancer research
-
In this episode, Professor Michael Hofman shares his experience with PSMA theranostics trials in prostate cancer, particularly focusing on the ProPSMA and TheraP trials.
He emphasises the advancements in PSMA PET imaging, highlighting its prognostic and predictive significance, as well as the importance of accurate imaging in guiding treatment decisions.
He also addresses the challenges of conducting imaging clinical trials and discusses the importance of industry collaboration in research.